Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Gallium-labelled PSMA-11 PET/CT and it’s benefits

Jeremie Calais • 6 Mar 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer

Jeremie Calais, MD, of the University of California, Los Angeles, CA, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA and discusses the use of gallium-labelled PSMA-11 PET/CT imaging in the screening of prostate cancer and it’s greatly increased specificity compared to other screening technologies.

More from Jeremie Calais

2:10
Exploring the new frontier: radionuclide therapy in metastatic prostate cancer
Jeremie Calais • 3 Jun 2023
4:16
PSMA PET guided salvage RT among patients with prostate cancer in the post-prostatectomy setting
Jeremie Calais • 3 Jun 2023
2:10
Integrating radioligand therapy for prostate cancer in US clinical practice
Jeremie Calais • 4 Jun 2023
2:56
PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study
Jeremie Calais • 4 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals